Ardelyx is a biopharmaceutical company focused on developing medicines to improve treatment for people with kidney and cardiorenal diseases. This includes patients with chronic kidney disease (CKD) on dialysis suffering from elevated serum phosphorus; and CKD patients and/or heart failure patients with elevated serum potassium (hyperkalemia). Co.'s portfolio includes tenapanor, a medicine for the control of serum phosphorus in adult patients with CKD on dialysis. Co. is also developing a small molecule potassium secretagogue program, RDX013, for the potential treatment of hyperkalemia. In addition, Co. has developed tenapanor for the treatment of patients with IBS-C. The ARDX stock yearly return is shown above.
The yearly return on the ARDX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the ARDX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|